Show simple item record

Authordc.contributor.authorSafadi, Marco Aurelio
Authordc.contributor.authorRiera Montes, Margarita
Authordc.contributor.authorBravo, Lulu
Authordc.contributor.authorTangsathapornpong, Auchara
Authordc.contributor.authorLagos Zuccone, Rosanna Marietta
Authordc.contributor.authorThisyakorn, Usa
Authordc.contributor.authorLinhares, Alexandre C.
Authordc.contributor.authorCapeding, Rose
Authordc.contributor.authorPrommalikit, Olarn
Authordc.contributor.authorVerstraeten, Thomas
Authordc.contributor.authorO'Ryan Gallardo, Miguel Luis
Admission datedc.date.accessioned2022-10-20T17:27:35Z
Available datedc.date.available2022-10-20T17:27:35Z
Publication datedc.date.issued2021
Cita de ítemdc.identifier.citationInternational Journal of Infectious Diseases 109 (2021) 77–84es_ES
Identifierdc.identifier.other10.1016/j.ijid.2021.06.037
Identifierdc.identifier.urihttps://repositorio.uchile.cl/handle/2250/188727
Abstractdc.description.abstractBackground: Noroviruses (NoVs) cause acute gastroenteritis (AGE) worldwide, affecting children in particular. We aimed to estimate the burden of disease due to NoV among children aged <6 years in Brazil, Chile, Philippines and Thailand. Methods: This was a prospective, hospital-based, observational study. Children were recruited over one year between 2014 and 2017. Four cohorts were analysed: community-acquired AGE outpatients and inpatients, nosocomial AGE inpatients, and asymptomatic outpatients. We collected demographic and clinical data, and a stool sample that was tested for NoV. Positive samples were tested for Rotavirus (RV) and NoV-genotyped. Disease severity was assessed by the Vesikari and modified Vesikari scores. Prevalence and incidence of NoV-AGE were estimated by cohort and country. Results: 1637 participants yielded valid laboratory results. The proportion of NoV-positive cases was 23.8% (95% CI 20.8-27.2) in the outpatient cohort, 17.9% (15.0-21.3) in the hospital cohort, 21.4% (12.7- 33.8) in the nosocomial cohort and 9.6% (6.9-13.2) in the asymptomatic cohort. Genotype GII.4 was predominant (58%). Less than 4% samples had RV coinfection. In general, NoV-positive subjects had more severe presentations than NoV-negative subjects. Conclusions: NoV caused AGE with substantial burden throughout the studied settings, with higher relative frequency in Brazil where RV vaccination coverage is high.es_ES
Patrocinadordc.description.sponsorshipTakeda Vaccines Inc. ANID - Millennium Science Initiative Program IMII P09/016-F ICN09_016es_ES
Lenguagedc.language.isoenes_ES
Publisherdc.publisherElsevieres_ES
Type of licensedc.rightsAttribution-NonCommercial-NoDerivs 3.0 United States*
Link to Licensedc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/3.0/us/*
Sourcedc.sourceInternational Journal of Infectious Diseaseses_ES
Keywordsdc.subjectGastroenteritises_ES
Keywordsdc.subjectNoroviruses_ES
Keywordsdc.subjectHospitales_ES
Keywordsdc.subjectCommunityes_ES
Keywordsdc.subjectNosocomiales_ES
Títulodc.titleThe burden of norovirus disease in children: a multi-country study in Chile, Brazil, Thailand and the Philippineses_ES
Document typedc.typeArtículo de revistaes_ES
dc.description.versiondc.description.versionVersión publicada - versión final del editores_ES
dcterms.accessRightsdcterms.accessRightsAcceso abiertoes_ES
Catalogueruchile.catalogadorcfres_ES
Indexationuchile.indexArtículo de publícación WoSes_ES
Indexationuchile.indexArtículo de publicación SCOPUSes_ES


Files in this item

Icon

This item appears in the following Collection(s)

Show simple item record

Attribution-NonCommercial-NoDerivs 3.0 United States
Except where otherwise noted, this item's license is described as Attribution-NonCommercial-NoDerivs 3.0 United States